Summary of COVID-19 epigallocatechin gallate studies

1. Zhu et al., Efficacy and safety of 7-day aerosolized epigallocatechin-3-gallate in oncologic patients with COVID-19 pneumonia

114 patient epigallocatechin gallate late treatment RCT: 38% greater improvement (p=0.002).
RCT 108 hospitalized oncologic patients with COVID-19 pneumonia showing significant benefit with aerosolized epigallocatechin-3-gallate (EGCG). The EGCG group showed significantly greater CT imaging improvement (64.8% vs 40.5%, P=0.004) and higher improvement rates for fever (OR 3.78, 95% CI 1.38-10.35) and dyspnea (OR 10.29, 95% CI 1.75-60.45).
Jan 2026, BMC Cancer, https://link.springer.com/10.1186/s12885-026-15553-x, https://c19p.org/zhu14